17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
The Ministry of Health’s Drug Advisory Committee has recommended:
- Fluticasone furoate/umeclid...
17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
The Ministry of Health’s Drug Advisory Committee has recommended:
- Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder for treating asthma; and
- Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) inhalation powder for treating chronic obstructive pulmonary disease.
Funding status
RFluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder are recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indications from 1 April 2025.
NRSDL subsidy does not apply to any formulations or strengths of beclomethasone dipropionate/glycopyrronium/formoterol, budesonide/glycopyrronium/formoterol, mometasone furoate/glycopyrronium/indacaterol, or tiotropium.
02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
The Ministry of Health’s Drug Advisory Committee has recommended:
- Umeclidinium 62.5mcg inhal...
02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
The Ministry of Health’s Drug Advisory Committee has recommended:
- Umeclidinium 62.5mcg inhalation powder for the:
- Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have breathlessness.
- Umeclidinium/vilanterol 62.5/25mcg inhalation powder for the:
- Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have frequent exacerbations (at least 2 per year or at least 1 leading to hospitalisation per year) and/or persistent breathlessness despite treatment with LAMA monotherapy.
- Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group D) with persistent symptoms and frequent exacerbations.
Subsidy status
RUmeclidinium 62.5mcg inhalation powder and umeclidinium/vilanterol 62.5/25mcg inhalation powder are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
NRSDL subsidies do not apply to the following:
- Other LAMAs (glycopyrronium, tiotropium or aclidinium)
- Other LAMA/LABAs (indacaterol/glycopyrronium, tiotropium/olodaterol or aclidinium/formoterol)